My Take: Shares of DE are down substantially over the past 12 months, but this company appears to be doing just fine. This stock is beginning to look like an excellent value.
Farfetch [FTCH] - Last Close: $4.34
New earnings data is boosting shares of Farfetch.
Late Thursday, the fashion platform reported better-than-expected Q1 earnings results, and the market is reacting favorably.
Farfetch's operating loss narrowed to $(0.16) per share, which was better than Wall Street's expectation of a $(0.29) per share loss.
Revenues of $556.4 million also surpassed the consensus of $515.4 million.
Analysts from Wedbush speculated that Farfetch could achieve adjusted EBITDA profitability this year, although EPS profitability could still be a ways off.
FTCH is up 23.7% in today's premarket.
My Take: FTCH's chart is pretty unimpressive, but its high short ratio of 11.47% could open the door to a violent rally if it can maintain its momentum.
Lucy's Scientific Discovery [LSDI] - Last Close: $1.08
Lucy's Scientific Discover is rallying after an announcement.
Yesterday, the psychedelic pharma firm announced it's teaming up with non-profit TheraPsil to advance medical psilocybin access and research.
The companies said the new collaboration will expand legal access to psilocybin therapy for Canadian patients with end-of-life distress and other conditions.
They will also collect real-world data to improve safety & treatment, using TheraPsi's Project Solace as a basis.
The partnership will also enable Lucy to introduce natural psilocybin products into the Canadian market, and allow the firm to gain early consumer feedback.
Shares rallied 16.7% on Thursday after the news broke, and LSDI is up another 37.9% in today's premarket.
My Take: LSDI is down substantially from its 52-week high, and its shares have been unable to get off the ground since the beginning of April. However, today's rally could kick-start this micro-cap stock.
NovaBay Pharma [NBY] - Last Close: $0.72
A regulatory disclosure is boosting shares of NovaBay Pharma.
After Thursday's close, the pharma firm filed a Form D that revealed it's planning an exempt $3 million offering of debt and warrants.
Only sparse details are available on the offering at the moment, but it appears that Ladenburgg Thalmann & Co helped broker the offering.
NovaBay is claiming an exemption under SEC Rule 506(b).
Shares of NBY are up 47.2% in today's premarket, on elevated trading volume.
My Take: I am not sure what's going on here. NBY has a 6.46% short ratio as of April 28th, so there could be some price manipulation going on here.
